CN102757478B - Allyl cysteinyl amino acid derivative and synthesis method and application thereof - Google Patents
Allyl cysteinyl amino acid derivative and synthesis method and application thereof Download PDFInfo
- Publication number
- CN102757478B CN102757478B CN2011101069320A CN201110106932A CN102757478B CN 102757478 B CN102757478 B CN 102757478B CN 2011101069320 A CN2011101069320 A CN 2011101069320A CN 201110106932 A CN201110106932 A CN 201110106932A CN 102757478 B CN102757478 B CN 102757478B
- Authority
- CN
- China
- Prior art keywords
- boc
- sac
- ome
- reaction
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Allyl cysteinyl amino acid derivative Chemical class 0.000 title claims abstract description 22
- 238000001308 synthesis method Methods 0.000 title abstract 3
- AMPHKYRLSOPVBX-YFKPBYRVSA-N allylcysteine Chemical compound OC(=O)[C@H](CS)NCC=C AMPHKYRLSOPVBX-YFKPBYRVSA-N 0.000 claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 17
- 230000001760 anti-analgesic effect Effects 0.000 claims abstract description 10
- 235000001014 amino acid Nutrition 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 99
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical group BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 230000000146 antalgic effect Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 239000003637 basic solution Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 235000004611 garlic Nutrition 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 244000245420 ail Species 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 73
- 238000002360 preparation method Methods 0.000 description 65
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 47
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 230000004913 activation Effects 0.000 description 15
- 239000011734 sodium Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 9
- 240000002234 Allium sativum Species 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001274216 Naso Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 108010092377 aminoalcoholphosphotransferase Proteins 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an allyl cysteinyl amino acid derivative and a synthesis method and application thereof. The synthesis method comprises the following steps: taking the most important active component allyl cysteine in garlic as a parent nucleus; performing amino acid modification on the parent nucleus to obtain the allyl cysteinyl amino acid derivative shown as a formula I, wherein pharmacokinetic properties of the parent nucleus are improved through structural modification, so as to improve the biological activity of the parent nucleus. Pharmacological and pharmacodynamic experiments show that the allyl cysteinyl amino acid derivative has excellent anti-inflammatory or analgesic activity and can be prepared into anti-inflammatory or analgesic medicines.
Description
Technical field
The present invention relates to oligopeptides, relate in particular to allyl cysteine amino acid derivative and synthetic method thereof with anti-inflammatory and analgesic activities, the invention further relates to their application in preparing anti-inflammatory or analgesic, belong to allyl cysteine amino acid derivative field.
Background technology
Inflammation is the major incentive of many major diseases (such as cancer, cardiovascular disorder and presenile dementia etc.).Preventing inflammation is early stage step and the committed step of the described major disease of prevention, and finding outstanding anti-inflammatory drug is one of focus of new drug research.
The garlic food and medicament dual-purpose effect history of existing several thousand, have the pharmacologically actives such as the body's immunity of raising, anti-inflammatory, antibiotic, hypotensive, reducing blood-fat in recent years along with the deep discovery garlicin of garlic pharmacology activity research.Wherein the anti-inflammatory action of garlic causes international concern gradually.Garlic has obvious inhibition or killing action to diplococcus of various pathogens such as staphylococcus, meningitis, pneumonia etc., can treat the inflammatory diseasess such as lobar pneumonia, pulmonary tuberculosis, wound suppuration, trachoma.The principle of garlicin antimicrobial antiphlogistic is because the sulphur atom of sulfocompound in garlic combines and suppressed the Growth and reproduction of bacterium with sulphur atom in the necessary halfcystine molecule of bacterial growth breeding.2009, Yung-Hyun Cho found that garlic can reduce bacterial growth when the treatment chronic bacterial prostatitis, the amelioration of inflammation reaction, and, when together with Ciprofloxacin, using, can work in coordination with effectiveness with its generation, reach better antiphlogistic effects.
Summary of the invention
One of purpose of the present invention is to provide the allyl cysteine amino acid derivative that a class has anti-inflammatory and antalgic activity;
Two of purpose of the present invention is to provide a kind of method of synthetic above-mentioned allyl cysteine amino acid derivative;
Three of the object of the invention is that described allyl cysteine amino acid derivative is prepared into to anti-inflammatory or analgesic medicine.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
Allyl cysteine amino acid derivative with anti-inflammatory and antalgic activity, its structural formula are shown in formula I:
Wherein, R is selected from hydrogen, CH
3, CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2CH (CH
3)
2, CH
2C
6H
4-OH-p, CH (OH) CH
3, Indole-5-yl-CH
2, CH
2CH
2CO
2CH
3, CH
2OH, CH
2CH
2CH
2CH
2NHCOCH (NH
2) CH
2SCH
2CHCH
2, CH
2CO
2CH
3, Imidazole-4-yl-CH
2, CH
2CH
2SCH
3Or CH
2C
6H
5.
Two of the object of the invention is to provide a kind of method of synthetic above-mentioned allyl cysteine amino acid derivative, and the method comprises:
1) Cys and the reaction of 3-bromopropylene obtain allyl cysteine (SAC);
2) allyl cysteine (SAC) with (BOC)
2Reaction, obtain Boc-SAC;
3) amino acid and methyl alcohol reaction obtain HClAA-OMe;
4) Boc-SAC and HClAA-OMe condensation obtain Boc-SAC-AA-OMe;
5) Boc-SAC-AA-OMe sloughs formicester and generates Boc-SAC-AA;
6) Boc-SAC-AA is removed to Boc, obtain.
Wherein, preferred, step 1), Cys react to three hours formation allyl cysteines (SAC) in ammoniacal liquor under 0 ℃ with the 3-bromopropylene;
Step 2) in preferred in containing the dioxane of alkalescent water SAC (allyl cysteine) with (BOC)
2Reaction, obtain Boc-SAC;
Step 3) preferred under the effect of sulfur oxychloride in, amino acid and methyl alcohol reaction obtain HClAA-OMe; Wherein, described amino acid is selected from Gly, Ala, Val, Ile, Leu, Tyr, Thr, Pro, Glu, Ser, Lys, Asp, Trp, Met or Phe;
Step 4) in, preferably under DCC and HOBt exist, Boc-SAC is condensed into Boc-SAC-AA-OMe with HClAA-OMe in anhydrous THF;
Step 5) preferred in containing the basic solution of NaOH in, Boc-SAC-AA-OMe sloughs formicester and generates Boc-SAC-AA;
Step 6) in preferred in the ethyl acetate of containing hydrogen chloride Boc-SAC-AA remove Boc and generate SAC-AA.
The present invention utilizes most important activeconstituents allyl cysteine in garlic to be parent nucleus, to it, carry out amino acid modified, obtain the allyl cysteine amino acid derivative shown in formula I, by its structural modification is improved to its medicine for character, and then improve the biological activity of parent nucleus.Pharmacology pharmacodynamic is tested and is shown, allyl cysteine amino acid derivative of the present invention has excellent anti-inflammatory or analgesic activities, it can be prepared into to anti-inflammatory or analgesic.
The present invention also provides a kind of anti-inflammatory or analgesic pharmaceutical composition, and this pharmaceutical composition is comprised of compound and the pharmaceutically acceptable carrier shown in the formula I of the upper significant quantity for the treatment of.Described carrier includes but not limited to: glucose, salt solution, glycerine, ethanol, distilled water etc.; Described pharmaceutical composition can be prepared into according to the drug formulation process of routine injection or oral preparations.For example, can be that carrier is prepared into injection formulations by it with physiological saline or the aqueous solution that contains glucose; Or according to the oral preparations method of routine, it is prepared into to oral preparations, and such as: the various oral preparations such as enteric coated capsule, colon site-specific drug.
The dosage of pharmaceutical composition of the present invention is the significant quantity in treatment, and concrete dosage should be with reference to factors such as route of administration and patient health situations, as a reference: every day about 3-120 microgram/Kg body weight, be preferably 35 micrograms/Kg body weight.
The accompanying drawing explanation
The structural formula of Fig. 1 allyl cysteine amino acid derivative of the present invention.
Fig. 2 allyl cysteine synthetic route of the present invention schematic diagram: i) 3-bromopropylene and ammoniacal liquor; Ii) (Boc)
2O and 2N NaOH; Iii) DCC, HOBt, NMM and amino acid methyl ester; Iv) 4N NaOH; V) hydrogenchloride ethyl acetate solution (4N); R is selected from hydrogen, CH
3, CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2CH (CH
3)
2, CH
2C
6H
4-OH-p, CH (OH) CH
3, Indole-5-yl-CH
2, CH
2CH
2CO
2CH
3, CH
2OH, CH
2CH
2CH
2CH2NHCOCH (NH
2) CH
2SCH
2CHCH
2, CH
2CO
2CH
3, Imidazole-4-yl-CH
2, CH
2CH
2SCH
3Or CH
2C
6H
5.
Embodiment
In order further to set forth the present invention, below provide a series of embodiment.These embodiment are illustrative fully, and they only are used for the present invention is specifically described, and not should be understood to limitation of the present invention.
In reaction flask, adding 9g (74.3mmol) Cys, is the NH of 2M with 200ml concentration
4OH adds 14g (115.7mmol) 3-bromopropylene after dissolving, and under 0 ℃, reflects 3h.Be concentrated into driedly, obtain colorless solid.Water-ethyl alcohol recrystallization obtains title compound.ESI-MS(m/e)：162[M+H]
+.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝5.85-5.65(m，1H)，5.05-5.20(m，2H)，3.75-3.85(m，1H)，3.05-3.18(d，J＝7.2Hz，2H)，2.80-3.05(m，2H).
Embodiment 2 preparation Boc-SAC
Take 640mg SAC in reaction flask, add the 8ml water dissolution, under condition of ice bath, slowly drip 1N NaOH 4ml, will be dissolved with 1.040mg (Boc)
2The dioxane of O is slowly poured into wherein, and adjusting reaction solution pH is 9, reaction 72h, during every 3h, with single-pass, take out CO in reaction system
2Once.The TLC detection reaction fully after, adjusting reaction solution pH is 7, revolve except dioxane, then to adjust reaction solution pH is 2, with ethyl acetate extraction reaction solution three times, the ethyl acetate layer that obtains extracts and washes three times with saturated NaCl again, obtains ethyl acetate layer anhydrous Na SO
4Dried overnight, remove by filter NaSO
4, be spin-dried for ethyl acetate and obtain title compound.ESI-MS(m/e)：282[M+H]
+.
Embodiment 3 preparation HClGly-OMe (1a)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Gly is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：89[M+H]
+
Embodiment 4 preparation HClAla-OMe (1b)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Ala is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：104[M+H]
+
Embodiment 5 preparation HClVal-OMe (1c)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Val is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：132[M+H]
+
Embodiment 6 preparation HCl HClIle-OMe (1d)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Ile is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：146[M+H]
+
Embodiment 7 preparation HCl HClLeu-OMe (1e)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Leu is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：146[M+H]
+
Embodiment 8 preparation HClTyr-OMe (1f)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Tyr is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：196[M+H]
+
Embodiment 9 preparation HClThr-OMe (1g)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Thr is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：134[M+H]
+
Embodiment 10 preparation HClPro-OMe (1h)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Pro is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：130[M+H]
+
Embodiment 11 preparation HClGlu-OMe
2(1i)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Glu is added in reaction system, reaction 36h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：176[M+H]
+
Embodiment 12 preparation HClSer-OMe (1j)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Ser is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：120[M+H]
+
Embodiment 13 preparation HClLys-OMe (1k)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Lys is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：161[M+H]
+
Embodiment 14 preparation HClAsp-OMe
2(1l)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Asp is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：162[M+H]
+
Embodiment 15 preparation HClTrp-OMe (1m)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Trp is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：219[M+H]
+
Embodiment 16 preparation HClMet-OMe (1n)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Met is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：164[M+H]
+
Embodiment 17 preparation HClPhe-OMe (1o)
Measure 30ml methyl alcohol, under condition of ice bath, slowly drip 2.6ml SOCl
2, activation 30min.10mmol L-Phe is added in reaction system, reaction 24h, the TLC detection reaction is complete, with single-pass, reaction solution is drained, and adds a small amount of methyl alcohol to drain, and 3 times repeatedly, then add a small amount of ether to drain, three times repeatedly, obtain title compound.ESI-MS(m/e)：180[M+H]
+
Embodiment 18 preparation Boc-SAC-Gly-OMe (2a)
Take 2.61g Boc-SAC in reaction flask, with a small amount of anhydrous THF, dissolve, under condition of ice bath, add 1-hydroxy benzo triazole (HoBt) 1.45g, after 5min, add again N, N '-dicyclohexylcarbodiimide (DCC), will be dissolved with 10mmol HClGly-OMe and pH and with NMM, be adjusted to 9 anhydrous THF and pour in reaction system after 20min.Reaction 12h, after the reflection fully of TLC detection display, by reacting liquid filtering, filtrate is spin-dried for the rear acetic acid ethyl dissolution of using, and uses successively 5%NaHCO
3Solution, saturated NaCl solution, 5%KHSO
4Solution, saturated NaCl solution, saturated NaHCO
3Solution, saturated NaCl solution extraction is washed three times, the ethyl acetate layer that obtains anhydrous Na SO
4Dried overnight.Remove by filter NaSO
4, filtrate being spin-dried for obtains title compound.ESI-MS(m/e)：355[M+Na]
+.Mp：48℃
(c＝0.51，CH
3OH).IR(KBr)：3313.71，3003.17，2972.31，1761.01，1101.35，985.62，925.83，705.95.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.45-8.25(t，J＝5.4Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)5.85-5.65(m，1H)，5.05-5.20(m，2H)，4.10-4.00(m，1H)，3.95-3.75(m，2H)，3.70-3.55(s，3H)，3.25-3.05(d，J＝6.9Hz，1H)，2.95-2.50(m，2H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.67，170.53，155.74，134.87，117.66，78.71，55.58，54.17，28.65，25.79，24.92.
Embodiment 19 preparation Boc-SAC-Ala-OMe (2b)
According to the method for embodiment 18, Boc-SAC and HClAla-OMe reaction, obtain title compound.ESI-MS(m/e)：369[M+Na]
+.Mp：64℃.
(c＝0.53，CH
3OH).IR(KBr)：3446.79，3319.49，3082.25，1749.44，1543.05，1166.93，1049.28，678.94.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.45-8.25(d，J＝7.2Hz，1H)，7.00-6.85(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.05-5.20(m，2H)，4.40-4.20(m，1H)，4.10-4.00(m，1H)，3.95-3.75(m，2H)，3.60(s，3H)，3.35-3.15(d，J＝4.5Hz，2H)，2.85-2.65(m，1H)，2.60-2.45(m，2H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝173.24，171.06，155.71，134.91，117.64，78.66，54.22，52.33，48.03，34.40，33.12，28.63，17.38.Elem.
Embodiment 20 preparation Boc-SAC-Val-OMe (2c)
According to the method for embodiment 18, Boc-SAC and HClVal-OMe reaction, obtain title compound.ESI-MS(m/e)：397[M+Na]
+.Mp：114℃.
(c＝0.51，CH
3OH).IR(KBr)：3323.35，2970.38，1751.36，1681.93，1649.14，1535.34，1290.38，1056.99，1022.27.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.05(d，J＝8.4Hz，1H)，7.05-6.95(d，J＝8.7Hz，1H)5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.30-4.10(m，2H)，3.70-3.55(s，3H)，3.25-3.05(d，J＝8.1Hz，2H)，2.95-2.50(m，3H)，2.15-1.95(m，1H)，1.40(s，9H)，1.00-0.75(t，J＝6.0Hz，5H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.17，171.48，155.68，134.88，117.64，78.70，57.71，54.36，52.18，34.35，32.79，30.52，28.60，19.31，18.53.Elem.
Embodiment 21 preparation Boc-SAC-Ile-OMe (2d)
According to the method for embodiment 18, Boc-SAC and HClIle-OMe reaction, obtain title compound.ESI-MS(m/e)：411[M+Na]
+.Mp：93℃.
(c＝0.49，CH
3OH).IR(KBr)：3321.42，1747.51，1649.14，1556.55，1286.52，1172.72，927.76.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.00(d，J＝8.1Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.30-4.10(m，2H)，3.70-3.55(s，3H)，3.25-3.05(d，J＝6.9Hz，2H)，2.80-2.65(m，1H)，2.15-1.95(m，3H)，1.90-1.70(m，1H)，1.40(s，9H)，1.00-0.75(m，5H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.13，171.33，155.66，134.92，128.82，128.26，117.58，78.76，56.72，54.39，52.10，36.89，34.43，31.03，15.77，11.50.Elem.
Embodiment 22 preparation Boc-SAC-Leu-OMe (2e)
According to the method for embodiment 18, Boc-SAC and HClLeu-OMe reaction, obtain title compound.ESI-MS(m/e)：411[M+Na]
+.Mp：98℃.
(c＝0.51，CH
3OH).IR(KBr)：3338.78，2980.02，1759.08，1683.86，2525.69，1367.53，1249.87，1155.36.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.00(d，J＝8.1Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.20(m，1H)，4.20-4.05(m，1H)，3.70-3.55(s，3H)，3.25-3.05(d，J＝8.2Hz，2H)，2.80-2.65(m，1H)，2.15-1.95(m，3H)，1.90-1.70(m，1H)，1.40(s，9H)，1.00-0.75(m，5H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝173.12，171.26，155.63，134.87，117.63，78.68，54.35，52.29，50.64，34.38，32.83，28.59，24.51，23.25，21.69.
Embodiment 23 preparation Boc-SAC-Tyr-OMe (2f)
According to the method for embodiment 18, Boc-SAC and HClTyr-OMe reaction, obtain title compound.ESI-MS(m/e)：461[M+Na]
+.
(c＝0.49，CH
3OH).IR(KBr)：3475.73，1753.29，1726.29，1446.61，1367.53，1269.16，1051.20，840.96.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.30-8.10(d，J＝7.5Hz，1H)，7.15-6.95(m，3H)，6.75-6.50(d，J＝8.4Hz，2H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.20(m，1H)，4.20-4.05(m，1H)，3.70-3.55(s，3H)，3.50-3.25(m，2H)，3.25-3.05(d，J＝8.2Hz，2H)，2.80-2.65(m，2H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.16，171.12，156.65，155.62，134.83，130.45，127.15，117.65，115.54，78.74，54.26，52.24，36.39，34.36，33.07，28.62.
Embodiment 24 preparation Boc-SAC-Thr-OMe (2g)
According to the method for embodiment 18, Boc-SAC and HClThr-OMe reaction, obtain title compound.ESI-MS(m/e)：376[M+Na]
+.Mp：65℃.
(c＝0.51，CH
3OH).IR(KBr)：3485.37，2517.10，1720.50，1670.35，1575.84，1506.41，1282.66，1195.87，1136.07.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.90-7.75(d，J＝8.7Hz，1H)，7.20-7.05(d，J＝8.7Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.70-3.55(s，3H)，3.45(s，1H)，3.25-3.10(m，2H)，2.80-2.65(m，1H)，2.60-2.45(m，2H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.69，171.33，155.76，134.95，117.62，78.77，66.71，58.07，54.47，52.33，34.32，32.83，28.62，20.47.
Embodiment 25 preparation Boc-SAC-Pro-OMe (2h)
According to the method for embodiment 18, Boc-SAC and HClPro-OMe reaction, obtain title compound.ESI-MS(m/e)：395[M+Na]
+.
(c＝0.52，CH
3OH).IR(KBr)：2980.02，1747.51，1733.86?1710.86，1647.21，1519.91，1488.11?1438.90，1365.60，1166.93，1045.42.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.20-7.05(d?J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，2H)，4.20-4.05(m，1H)，3.70-3.55(s，3H)，3.45(s，1H)，3.45-3.10(m，3H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，2.40-2.05(m，1H)，2.05-1.75(m，3)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.57，169.67，155.31，135.01，117.55，78.60，59.07，46.98，40.85，40.29，34.66，33.09，25.02.
Embodiment 26 preparation Boc-SAC-Glu-OMe (2i)
According to the method for embodiment 18, Boc-SAC and HClGlu-OMe reaction, obtain title compound.ESI-MS(m/e)：441[M+Na]
+.Mp：105℃
(c＝0.52，CH
3OH).IR(KBr)：3315.63，1749.44，1726.29，1656.85，1517.98，1436.97，1161.15，1112.93，920.05.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝8.5Hz，1H)，7.05-6.90(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.70-3.65(s，3H)，3.65-3.55(s，3H)，3.45(m，1H)，3.25-3.10(m，2H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，2.45-2.30(t，J＝7.5Hz，1H)，2.15-1.95(m，1H)，1.95-1.75(m，1H)，1.40(s，9H)，1.15-1.05(t，J＝7.5Hz，1H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝173.02，171.71，168.00，134.39，118.26，65.35，52.49，52.10，51.85，48.99，34.38，31.54，29.92，26.47，15.53.
Embodiment 27 preparation Boc-SAC-Ser-OMe (2j)
According to the method for embodiment 18, Boc-SAC and HClSer-OMe reaction, obtain title compound.ESI-MS(m/e)：364[M+H]
+.
(c＝0.52，CH
3OH).IR(KBr)：3599.64，2998.95，1651.57，1435.55，1431.12，1334.09，1128.73，1205.49，1005.26，994.66.
1HNMR(300MHz，DMSO-d
6)：δ/pp＝8.40-8.20(d，J＝7.5Hz，1H)，7.05-6.90(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.75-3.25(m，1H)，3.70-3.65(s，3H)，3.45-3.30(m，1H)，3.25-3.10(d，J＝4.8Hz?3H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.37，171.24，155.53，134.92，117.62，78.71，63.33，61.63，55.62，55.06，54.24，53.24，52.34，49.05，39.08，33.14，28.61.
Embodiment 28 preparation 2 (Boc-SAC)-Lys-OMe (2k)
According to the method for embodiment 18, Boc-SAC and HClLys-OMe reaction, obtain title compound.ESI-MS(m/e)：669[M+Na]
+.
(c＝0.48，CH
3OH).IR(KBr)：3275.13，2931.80，1747.51，1639.49，1699.67，1533.41，1249.87，1172.72，1049.28，1022.27，920.77.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝8.5Hz，1H)，7.95-7.85(t，J＝4.8Hz，1H)，6.95-6.90(d，J＝8.7Hz，1H)，6.95-6.80(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.20-4.15(m，1H)，4.15-4.08(m，1H)，4.05-4.00(m，1H)，3.70-3.65(s，3H)，3.30(s，1H)，3.20-3.10(t，J＝8.2Hz，4H)，2.80-2.60(m，2H)，2.60-2.55(m，4H)，1.80-1.55(m，2H)，1.40(s，20H)，1.30-1.20(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.74，171.29，170.75，155.66，134.88，134.84，117.64，78.69，52.30，52.27，34.41，34.28，33.01，28.95，28.62，22.91.
Embodiment 29 preparation Boc-SAC-Asp-OMe
2(2l)
According to the method for embodiment 18, Boc-SAC and HClAsp-OMe
2Reaction, obtain title compound.ESI-MS(m/e)：547[M+Na]
+.Mp：107℃
(c＝0.52，CH
3OH).IR(KBr)：3354.21，2933.73，1795.08，1649.14，1521.84，1436.97，1367.53，1166.93，1056.99，929.69.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.45-7.55(d，J＝5.4Hz，1H)，6.65-6.55(d，J＝7.5Hz，1H)，6.15-6.00(d，J＝5.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，5.25-5.05(m，4H)，4.85-4.65(m，2H)，4.65-4.45(m，1H)，3.85-3.75(s，3H)，3.75-3.65(s，3H)，3.55-3.45(m，3H)，3.25-3.10(m，4H)，2.55-2.75(m，1H)，1.95-1.75(m，1H)，1.40(s，9H)，1.30-1.15(t，J＝6.9Hz，4H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.04，170.87，133.71，133.63，117.97，117.83，65.81，52.62，52.53，52.10，35.09，35.07，32.60，32.43，28.32，15.24.
Embodiment 30 preparation Boc-SAC-Trp-OMe (2m)
According to the method for embodiment 18, Boc-SAC and HClTrp-OMe reaction, obtain title compound.ESI-MS(m/e)：464[M+H]
+.Mp：115℃
(c＝0.52，CH
3OH).IR(KBr)：3311.78，2915.09，2835.36，1737.86，1361.74，1338.60，1249.87，1217.06，927.76
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝10.95-10.85(s，1H)，8.30-8.20(m，1H)，7.55-7.45(d，J＝7.5Hz，1H)，7.40-7.35(d，J＝8.1Hz，1H)，7.20-7.15(s，1H)，7.15-6.90(m，3H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.65-3.55(s，3H)，3.25-3.10(m，4H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/pp＝172.40，171.20，155.68，136.55，134.84，127.53，124.16，121.44，118.91，118.42，117.64，111.89，109.52，78.77，54.32，53.50，52.28，34.38，33.13，28.61，27.47.
Embodiment 31 preparation Boc-SAC-Met-OMe (2n)
According to the method for embodiment 18, Boc-SAC and HClMet-OMe reaction, obtain title compound.ESI-MS(m/e)：407[M+H]
+.Mp：65℃.
(c＝0.53，CH
3OH).IR(KBr)：3547.09，3116.97，1907.60，1707.60，1761.01，1558.48，1521.84，1290.38，1274.95，775.68.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.30-8.20(d，J＝7.8Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.65(s，3H)，3.25-3.10(d，J＝7.2Hz，2H)，2.80-2.65(m，1H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.41，171.42，155.67，154.81，134.80，117.69，78.70，54.36，52.43，51.25，34.34，32.67，30.96，29.82，28.60，15.02.
Embodiment 32 preparation Boc-SAC-Phe-OMe (2o)
According to the method for embodiment 18, Boc-SAC and HClPhe-OMe reaction, obtain title compound.ESI-MS(m/e)：445[M+Na]
+.Mp：80℃
(c＝0.50，CH
3OH).IR(KBr)：3348.42，2980.02，2360.87，2339.65，1739.79，1656.85，1525.69，1392.61，1022.27，700.16.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝7.5Hz，2H)，6.95-6.85(d，J＝8.4Hz，2H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.65(s，3H)，3.50-3.35(s，3H)，3.25-3.10(d，J＝7.2Hz，2H)，3.10-3.00(m，2H)，2.80-2.65(m，2H)，1.40(s，9H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.05，171.17，155.59，137.41，134.83，129.56，128.69，127.01，117.65，78.71，54.32，53.91，52.31，37.08，34.36，33.06，28.62.
Embodiment 33 preparation Boc-SAC-Gly (3a)
Take Boc-SAC-Gly-OMe 800mg in reaction flask, with a small amount of tetrahydrofuran (THF), dissolve, under ice bath, slowly drip the NaOH solution of 2N until reaction solution pH is 13, reaction process keeps ice bath, reaction 2.5h.The TLC monitoring reaction is used saturated KHSO after finishing
4Conditioned reaction liquid pH is 7, revolves except tetrahydrofuran (THF), then is 2 by the reaction solution pH regulator, with the ethyl acetate extraction, washes reaction solution three times, and the ethyl acetate layer that obtains, with saturated NaCl washing three times, spends the night with anhydrous sodium sulfate drying subsequently.Filtering sodium sulfate, revolve and namely obtain title compound except ethyl acetate.
Embodiment 34 preparation Boc-SAC-Ala (3b)
Method according to embodiment 33, prepare title compound by Boc-SAC-Ala-OMe.
Embodiment 35 preparation Boc-SAC-Val (3c)
Method according to embodiment 33, prepare title compound by Boc-SAC-Val-OMe.
Embodiment 36 preparation Boc-SAC-Ile (3d)
Method according to embodiment 33, prepare title compound by Boc-SAC-Ile-OMe.
Embodiment 37 preparation Boc-SAC-Leu (3e)
Method according to embodiment 33, prepare title compound by Boc-SAC-Leu-OMe.
Embodiment 38 preparation Boc-SAC-Tyr (3f)
Method according to embodiment 33, prepare title compound by Boc-SAC-Tyr-OMe.
Embodiment 39 preparation Boc-SAC-Thr (3g)
Method according to embodiment 33, prepare title compound by Boc-SAC-Thr-OMe.
Embodiment 40 preparation Boc-SAC-Pro (3h)
Method according to embodiment 33, prepare title compound by Boc-SAC-Pro-OMe.
Embodiment 41 preparation Boc-SAC-Glu (3i)
According to the method for embodiment 33, by Boc-SAC-Glu-OMe
2Prepare title compound.
Embodiment 41 preparation Boc-SAC-Ser (3j)
Method according to embodiment 33, prepare title compound by Boc-SAC-Ser-OMe.
Embodiment 42 preparation 2 (Boc-SAC)-Lys (3k)
According to the method for embodiment 33, by 2 (Boc-SAC)-Lys-OMe, prepare title compound.
Embodiment 43 preparation Boc-SAC-Asp (3l)
According to the method for embodiment 33, by Boc-SAC-Asp-OMe
2Prepare title compound.
Embodiment 44 preparation Boc-SAC-Trp (3m)
Method according to embodiment 33, prepare title compound by Boc-SAC-Trp-OMe.
Embodiment 45 preparation Boc-SAC-Met (3n)
Method according to embodiment 33, prepare title compound by Boc-SAC-Met-OMe.
Embodiment 46 preparation Boc-SAC-Phe (3o)
Method according to embodiment 33, prepare title compound by Boc-SAC-Phe-OMe.
Embodiment 46 preparation SAC-Gly (4a)
Take 600mg Boc-SAC-Gly in reaction flask, with a small amount of anhydrous ethyl acetate, dissolve, under condition of ice bath, slowly drip 4N hydrochloric ethyl acetate 9ml, reaction continues 2h under the condition of drying, ice bath.The TLC monitoring reaction finishes, and reaction solution is drained with water pump, adds a small amount of dry ethyl acetate repeatedly to drain three times, then adds a small amount of anhydrous diethyl ether to drain, three times repeatedly.Namely obtain title compound.ESI-MS(m/e)：219[M+H]
+.Mp：89℃
(c＝0.49，CH
3OH).IR(KBr)：2935.66，1680.00，1579.70，1519.91，1398.39，1249.87，993.34，933..55.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.45-8.25(t，J＝5.4Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.05-5.20(m，2H)，4.10-4.00(m，1H)，3.95-3.75(m，2H)，3.25-3.05(d，J＝6.9Hz，1H)，2.95-2.50(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝170.07，168.37，134.47，51.99，41.14，34.38，31.62.
Embodiment 47 preparation SAC-Ala (4b)
Method according to embodiment 46, prepare title compound by Boc-SAC-Ala.ESI-MS(m/e)：233[M+H]
+.Mp：127℃.
(c＝0.51，CH
3OH).IR(KBr)：2924.09，1735.93，1674.21，1562.34，1489.05，1213.23，1138.00，991.41，923.90.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.45-8.25(d，J＝7.2Hz，1H)，7.00-6.85(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.05-5.20(m，2H)，4.40-4.20(m，1H)，4.10-4.00(m，1H)，3.95-3.75(m，2H)，3.35-3.15(d，J＝4.5Hz，2H)，2.85-2.65(m，1H)，2.60-2.45(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝173.68，172.43，167.34，134.44，118.33，51.94，48.29，48.19，34.36，31.56，21.21，17.24.
Embodiment 48 preparation SAC-Val (4c)
Method according to embodiment 46, prepare title compound by Boc-SAC-Val.ESI-MS(m/e)：261[M+H]
+.
(c＝0.51，CH
3OH).IR(KBr)：2488.17，1687.71，1541.12，1213.23，1143.79，989.48，921.97.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.05(d，J＝8.4Hz，1H)，7.05-6.95(d，J＝8.7Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.30-4.10(m，2H)，3.25-3.05(d，J＝8.1Hz，2H)，2.95-2.50(m，3H)，2.15-1.95(m，1H)，1.00-0.75(t，J＝6.0Hz，5H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.60，167.99，134.45，118.31，58.09，51.98，34.46，31.84，30.47，19.53，18.48.
Embodiment 49 preparation SAC-Ile (4d)
Method according to embodiment 46, prepare title compound by Boc-SAC-Ile.ESI-MS(m/e)：275[M+H]
+.
(c＝0.48，CH
3OH).IR(KBr)：3271.27，2922.16，1654.92，1527.62，1367.53，1166.93，921.97.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.00(d，J＝8.1Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.30-4.10(m，2H)，3.25-3.05(d，J＝6.9Hz，2H)，2.80-2.65(m，1H)，2.15-1.95(m，3H)，1.90-1.70(m，1H)，1.00-0.75(m，5H).
13CNMR(75MHz，DMSO-d
6)：δ/ppm＝172.58，167.86，134.41，57.10，51.92，37.02，34.39，31.74，25.12，15.98，11.86.
Embodiment 50 preparation SAC-Leu (4e)
Method according to embodiment 46, prepare title compound by Boc-SAC-Leu.ESI-MS(m/e)：275[M+H]
+.
(c＝0.49，CH
3OH).IR(KBr)：2922.16，1722.43，1672.28，1550.77，1471.69，1201.65，92.05.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.15-8.00(d，J＝8.1Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.30-4.10(m，2H)，3.25-3.05(d，J＝6.9Hz，2H)，2.80-2.65(m，1H)，2.15-1.95(m，3H)，1.90-1.70(m，1H)，1.00-0.75(m，5H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.58，167.86，134.41，57.10，51.92，37.02，34.39，31.74，25.12，15.98，11.86.
Embodiment 51 preparation SAC-Tyr (4f)
Method according to embodiment 46, prepare title compound by Boc-SAC-Tyr.ESI-MS(m/e)：325[M+H]
+.
(c＝0.51，CH
3OH).IR(KBr)：2783.28，1722.43，1516.05，1228.66，1105.21，925.83，839.03，734.88，542.00.
1H?NMR(300MHz，DMSO-d
6)：δ/ppm＝8.30-8.10(d，J＝7.5Hz，1H)，7.15-6.95(m，3H)，6.75-6.50(d，J＝8.4Hz，2H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.20(m，1H)，4.20-4.05(m，1H)，3.50-3.25(m，2H)，3.25-3.05(d，J＝8.2Hz，2H)，2.80-2.65(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.65，167.90，156.68，134.48，130.54，127.05，118.32，115.64，65.38，54.83，52.40，51.09，36.28，34.43，15.64.
Embodiment 52 preparation SAC-Thr (4g)
Method according to embodiment 46, prepare title compound by Boc-SAC-Thr.ESI-MS(m/e)：263[M+H]
+.
(c＝0.53，CH
3OH).IR(KBr)：3080.32，1681.93，2785.21，1942.32，1558.48，1463.97，1377.17，1207.44?1132.21，1055.06.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.90-7.75(d，J＝8.7Hz，1H)，7.20-7.05(d，J＝8.7Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.45(s，1H)，3.25-3.10(m，2H)，2.80-2.65(m，1H)，2.60-2.45(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.44，171.81，168.17，134.49，118.32，66.72，58.50，51.89，34.32，31.99，20.84.
Embodiment 53 preparation SAC-Pro (4h)
Method according to embodiment 46, prepare title compound by Boc-SAC-Pro.ESI-MS(m/e)：258[M+H]
+.Mp：114.9-115.2℃
(c＝0.53，CH
3OH).IR(KBr)：2891.30，1616.35，1409.96，1369.46，1224.80，1190.08，991.41，918.12，738.74
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.20-7.05(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，2H)，4.20-4.05(m，1H)，3.45(s，1H)，3.45-3.10(m，3H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，2.40-2.05(m，1H)，2.05-1.75(m，3H)
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.37，169.48，134.75，118.42，60.22，47.00，39.35，32.18，30.49，28.62，22.25.
Embodiment 54 preparation SAC-Glu (4i)
Method according to embodiment 46, prepare title compound by Boc-SAC-Glu.ESI-MS(m/e)：290[M+H]
+.
(c＝0.49，CH
3OH).IR(KBr)：3300.20，2432.24，1737.86，1666.50，1558.48，1487.12，1408.04，1228.66，1116.78，991.41，921.97.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝8.5Hz，1H)7.05-6.90(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.45(m，1H)，3.25-3.10(m，2H)，2.80-2.65(m，1H)，2.60-2.45(m，1H)，2.45-2.30(t，J＝7.5Hz，1H)，2.15-1.95(m，1H)，1.95-1.75(m，1H)，1.15-1.05(t，J＝7.5Hz，1H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝1174.12，172.86，167.84，134.44，118.35，51.94，34.41，31.64，30.41，26.88，21.54.
Embodiment 55 preparation SAC-Ser (4j)
Method according to embodiment 46, prepare title compound by Boc-SAC-Ser.ESI-MS(m/e)：249[M+H]
+.
(c＝0.50，CH
3OH).IR(KBr)：3194.12，1720.50，1672.28，1552.70，1490.97，1384.89，1205.51，1124.50，1047.35，991.41，927.76，738.74.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝7.5Hz，1H)，7.05-6.90(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.75-3.25(m，1H)，3.45-3.30(m，1H)，3.25-3.10(d，J＝4.8Hz，3H)，2.80-2.65(m，1H)，2.60-2.45(m，1H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.53，167.72，134.43，128.70，128.17，118.38，61.46，60.24，51.91，34.42，34.26，21.22，14.54.
Embodiment 56 preparation 2SAC-Lys (4k)
According to the method for embodiment 46, by 2 (Boc-SAC) Lys-OH, prepare title compound.ESI-MS(m/e)：433M+H]
+.
(c＝0.48，CH
3OH).IR(KBr)：2924.09，2532.54，1674.21，1562.34，1458.18，1379.10，1217.08，1128.36，991.41，923.90.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝8.5Hz，1H)，7.95-7.85(t，J＝4.8Hz，1H)，6.95-6.90(d，J＝8.7Hz，1H)，6.95-6.80(d，J＝8.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.20-4.15(m，1H)，4.15-4.08(m，1H)，4.05-4.00(m，1H)，3.30(s，1H)，3.20-3.10(t，J＝8.2Hz，4H)，2.80-2.60(m，2H)，2.60-2.55(m，4H)，1.80-1.55(m，2H)，1.30-1.20(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝173.12，172.40，167.88，134.46，134.33，118.45，118.38，60.23，51.91，34.37，34.20，31.73，31.29，28.62，21.48，21.22.
Embodiment 57 preparation SAC-Asp (4l)
Method according to embodiment 46, prepare title compound by Boc-SAC-Asp.ESI-MS(m/e)：420[M+H]
+.Mp：124℃
(c＝0.52，CH
3OH).IR(KBr)：3369.64，2926.01，1734.01，1651.07，1523.76，1440.83，1402.25，1321.34，1062.78，933.555.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝7.45-7.55(d，J＝5.4Hz，1H)，6.65-6.55(d，J＝7.5Hz，1H)，6.15-6.00(d，J＝5.1Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.85-4.65(m，2H)，4.65-4.45(m，1H)，3.85-3.75(s，3H)，3.75-3.65(s，3H)，3.55-3.45(m，3H)，3.25-3.10(m，4H)，2.55-2.75(m，1H)，1.95-1.75(m，1H)，1.30-1.15(t，J＝6.9Hz，4H).
13CNMR(75MHz，DMSO-d
6)：δ/ppm＝172.16，171,76，169.01，168.40，133.64，134.60，118.08，118.01，52.54，35.79，34.63，34.59，31.95，31.74.
Embodiment 58 preparation SAC-Trp (4m)
Method according to embodiment 46, prepare title compound by Boc-SAC-Trp-OH.ESI-MS(m/e)：348[M+H]
+.Mp：123℃
(c＝0.53，CH
3OH).IR(KBr)：2920.23，2814.14，2771.71，1489.05，1338.60，1228.66，1207.44，929.69，742.59.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝10.95-10.85(s，1H)，8.30-8.20(m，1H)，7.55-7.45(d，J＝7.5Hz，1H)，7.40-7.35(d，J＝8.1Hz，1H)，7.20-7.15(s，1H)，7.15-6.90(m，3H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.25-3.10(m，4H)，2.80-2.65(m，1H)，2.60-2.45(m，1H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝171.53，167.62，134.43，128.86，128.34，118.38，60.24，55.46，51.91，34.42，31.56，21.22，14.54.
Embodiment 59 preparation SAC-Met (4n)
Method according to embodiment 46, prepare title compound by Boc-SAC-Met-OH.ESI-MS(m/e)：293[M+H]
+.
(c＝0.52，CH
3OH).IR(KBr)：3331.07，3001.24，3205.69，3028.24，2771.71，2445.74，1739.79，1668.43，1174.65，929.69.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.30-8.20(d，J＝7.8Hz，1H)，7.05-6.95(d，J＝8.4Hz，1H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.25-3.10(d，J＝7.2Hz，2H)，2.80-2.65(m，1H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.88，172.40，167.86，134.46，118.34，65.36，60.21，34.42，33.78，31.64，31.19，29.98，25.81，24.88，21.21，15.62.
Embodiment 60 preparation SAC-Phe (4o)
Method according to embodiment 46, prepare title compound by Boc-SAC-Phe.ESI-MS(m/e)：309[M+H]
+.
(c＝0.53，CH
3OH).IR(KBr)：2875.86，2333.87，1726.29，1672.28，1548.84，1496.76，1406.11，1215.15，1109.07，991.41，923.90.
1HNMR(300MHz，DMSO-d
6)：δ/ppm＝8.40-8.20(d，J＝7.5Hz，2H)，6.95-6.85(d，J＝8.4Hz，2H)，5.85-5.65(m，1H)，5.25-5.05(m，2H)，4.40-4.25(m，1H)，4.20-4.05(m，1H)，3.65(s，3H)，3.25-3.10(d，J＝7.2Hz，2H)，3.10-3.00(m，2H)，2.80-2.65(m，2H).
13C?NMR(75MHz，DMSO-d
6)：δ/ppm＝172.44，167.82，137.66，134.54，129.74，128.73，127.02，118.27，54.49，51.95，37.02，34.47，32.00，21.56.
The anti-inflammatory activity evaluation experimental of experimental example 1 compound 4a-o of the present invention
The compound 4a-o (embodiment 46-60 is prepared) that the embodiment of the present invention is prepared and acetylsalicylic acid physiological saline wiring solution-forming (2 μ mol/ml); (20 ± 2g) are divided into blank group, acetylsalicylic acid group and 4a-o group, every group of 15 mouse to male ICR mouse at random.Gavage gave compound 4a-o (dosage is 20 μ mol/kg) or acetylsalicylic acid (dosage is 165 μ mol/kg) administration after 30 minutes respectively, toward the left ear gabarit of small white mouse, was coated with 0.03ml dimethylbenzene.After 2 hours, small white mouse cervical vertebra dislocation execution, two ears are got to circular auricle, weigh, justified the weight difference of auricles to two as swelling with the punch tool of diameter 7mm.Result is listed table 1 in.
The restraining effect of table 1 compound 4a-o to mice ear
N=15; A) with the NS group, compare P<0.05; .; .
The anti-inflammatory activity evaluation experimental of experimental example 2 the compounds of this invention 4h various dose
According to the method for experimental example 1 by 4h by 2 μ mol/kg, 20 μ mol/kg ,/00 μ mol/kg Three doses is to the male ICR mouse gavage, the weight differences of two circle auricles are listed table 2 in.
The restraining effect of table 2 various dose 4h to mouse swelling
N=15; A) with the NS group, compare P<0.01; B) with 20 μ mol/kg groups, compare,, P<0.01
The hot tail-flick method of experimental example 3 mouse optical radiation is estimated the analgesic activity of 4a-o
Male ICR mouse (20 ± 2g), before experiment, under experimental temperature, raised one day.Mouse is packed in special stationary magazine creel, outside afterbody is exposed to.The light beam irradiates mouse tail that produces with baby spot while surveying pain, start to whipping response latency (tail flick latency, TFL) from irradiation with the stopwatch meter.Regulating spot light lamp and mouse back range is 2-6s from making the comparatively sensitive TFL of stimulus intensity.When experiment starts, first survey 3 times, every minor tick 5min, get average as Basic Pain Threshold.Compound 4a-o of the present invention is mixed with in the 2 μ mol/ml aqueous solution, gastric infusion, each gavage amount is 0.2ml, dosage is 20 μ mol/kg.Each test is established the physiological saline group and is made parallel control.For preventing skin scald, illumination 15s dead line, interval 30min repetition measurement TFL is to observe the medicine analgesic time-effect relationship.With threshold of pain increase rate evaluation medicine analgesic intensity: PTV=AAPT/BPT (PTV=threshold of pain increase rate, BPT=Basic Pain Threshold value, threshold of pain after the AAPT=administration-Basic Pain Threshold value).The result that obtains is listed table 3 in.
Experimental result shows that compound 4a-o of the present invention all has clear and definite analgesic activity
The analgesic activity of table 3 the compounds of this invention 4a-o
Threshold of pain increase rate represents with mean ± SD%, n=15; A) with the NA group, compare P<0.001; B) with the NS group, compare P<0.01; C) with the NS group, compare P<0.05.
The analgesic activity experiment of experimental example 4 the compounds of this invention 4h various dose
Adopt experimental example 3 the hot whipping model evaluation of mouse optical radiation the analgesic activity of 2 μ mol/kg, 20 μ mol/kg and 200 μ mol/kg Three doses 4h.Result is listed table 4 in.
Experimental result shows that the compounds of this invention 4h has dose-dependent analgesic activity.
The analgesic activity of 4h under table 4 different dosing dosage
Threshold of pain increase rate represents with mean ± SD%, n=10; A) with the NS group, compare P<0.001; B) with the NS group, compare P>0.05.
Claims (9)
1. the allyl cysteine amino acid derivative that has anti-inflammatory and antalgic activity, its structural formula are shown in the formula I:
The formula I
Wherein, R is selected from hydrogen, CH
3, CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2CH (CH
3)
2, CH
2C
6H
4-OH-p, CH (OH) CH
3, Indole-5-yl-CH
2, CH
2CH
2CO
2CH
3, CH
2OH, CH
2CH
2CH
2CH
2NHCOCH (NH
2) CH
2SCH
2CHCH
2, CH
2CO
2CH
3, Imidazole-4-yl-CH
2, CH
2CH
2SCH
3Or CH
2C
6H
5.
2. synthesize the method for the described allyl cysteine amino acid derivative of claim 1, the method comprises:
1) Cys and the reaction of 3-bromopropylene obtain allyl cysteine;
2) allyl cysteine with (BOC)
2The O reaction, obtain Boc-SAC;
3) under the sulfur oxychloride effect, amino acid and methyl alcohol reaction obtain HClAA-OMe;
4) Boc-SAC and HClAA-OMe condensation obtain Boc-SAC-AA-OMe;
5) Boc-SAC-AA-OMe sloughs methyl esters and generates Boc-SAC-AA;
6) Boc-SAC-AA is removed to Boc, obtain;
Wherein, described amino acid is selected from Gly, Ala, Val, Ile, Leu, Tyr, Thr, Pro, Glu, Ser, Lys, Asp, Trp, Met or Phe.
3. it is characterized in that in accordance with the method for claim 2: in step 1), Cys is reacted under 0 ° of C with the 3-bromopropylene in ammoniacal liquor and formed allyl cysteine in three hours.
4. it is characterized in that: step 2 in accordance with the method for claim 2) in containing the dioxane of alkalescent water allyl cysteine with (BOC)
2Reaction, obtain Boc-SAC.
5. in accordance with the method for claim 2, it is characterized in that: step 4) under DCC and HOBt exist, Boc-SAC is condensed into Boc-SAC-AA-OMe with HClAA-OMe in anhydrous THF.
6. in accordance with the method for claim 2, it is characterized in that: step 5) in containing the basic solution of NaOH, Boc-SAC-AA-OMe sloughs formicester and generates Boc-SAC-AA.
7. it is characterized in that: step 6 in accordance with the method for claim 2) in the ethyl acetate of containing hydrogen chloride Boc-SAC-AA remove Boc and generate SAC-AA.
8. the purposes of allyl cysteine amino acid derivative claimed in claim 1 in preparing anti-inflammatory or analgesic.
9. an anti-inflammatory or analgesic pharmaceutical composition, is characterized in that: the upper significant quantity allyl cysteine amino acid derivative claimed in claim 1 for the treatment of and pharmaceutically acceptable carrier, consist of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101069320A CN102757478B (en) | 2011-04-27 | 2011-04-27 | Allyl cysteinyl amino acid derivative and synthesis method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101069320A CN102757478B (en) | 2011-04-27 | 2011-04-27 | Allyl cysteinyl amino acid derivative and synthesis method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102757478A CN102757478A (en) | 2012-10-31 |
| CN102757478B true CN102757478B (en) | 2013-11-20 |
Family
ID=47052157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101069320A Expired - Fee Related CN102757478B (en) | 2011-04-27 | 2011-04-27 | Allyl cysteinyl amino acid derivative and synthesis method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102757478B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110681362B (en) * | 2019-09-26 | 2020-09-11 | 浙江大学 | Mixed-mode chromatography medium with carboxyl and indolyl as functional groups |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467991A (en) * | 2007-08-02 | 2009-07-01 | 复旦大学 | Uses of allyl cysteine and analogue thereof in preparing medicament for treating myocardial damage |
| CN101880315A (en) * | 2009-05-08 | 2010-11-10 | 北京大学 | Branch oligopeptide with analgesic activity, preparation method and application thereof |
-
2011
- 2011-04-27 CN CN2011101069320A patent/CN102757478B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467991A (en) * | 2007-08-02 | 2009-07-01 | 复旦大学 | Uses of allyl cysteine and analogue thereof in preparing medicament for treating myocardial damage |
| CN101880315A (en) * | 2009-05-08 | 2010-11-10 | 北京大学 | Branch oligopeptide with analgesic activity, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102757478A (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661367T3 (en) | CDC7 kinase inhibitors and their uses | |
| CN105308055B (en) | Annelated pyrimidines class of trifluoromethyl substitution and application thereof | |
| CN109415360A (en) | For inhibiting the active compound of SHP2 and composition | |
| CN110430880A (en) | The alternatively condensed heterocyclic compouds of property BMP inhibitor | |
| EA003510B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| CN103694242A (en) | Pyrazolopyrimidine compound and pharmaceutical composition thereof as well as pharmaceutical application of pyrazolopyrimidine compound | |
| CN109574993A (en) | Substituted pyrimidine diethylenediamine compound and application thereof | |
| ES2689023T3 (en) | Piperidinyl-tetrahydroquinolines substituted and their use as antagonists of the alpha-2c adrenergic receptor | |
| CN113416170A (en) | Pentaazamacrocycle complexes with oral bioavailability | |
| CN106916177A (en) | A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes | |
| CN110234636A (en) | Composition comprising methylphenidate prodrug, method of manufacture and use thereof | |
| CN109415343A (en) | For treating substituted 2,4- diamino-quinoline of proliferative diseases | |
| EP3268046A1 (en) | Conjugates for treating diseases | |
| CN102757477B (en) | Allyl cysteinyl amino acid methyl ester derivative and synthesis method and application thereof | |
| CN106029657A (en) | Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists | |
| CN102757478B (en) | Allyl cysteinyl amino acid derivative and synthesis method and application thereof | |
| CN101531613A (en) | Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof | |
| AU2015268575B2 (en) | Derivative of butylphthalide and preparation method and use thereof | |
| CN104725363B (en) | Substituted diethylenediamine compound and its application method and purposes | |
| CN101580530A (en) | Amino acid conjugate prodrug of pentacyclic triterpenoid and medical application thereof | |
| CN107137715B (en) | A kind of 9-hydroxy-risperidone polyethylene glycol conjugation prodrug and preparation | |
| JPH09208496A (en) | Composition containing lh-rh antagonist | |
| TW577741B (en) | Novel pharmaceutical combination for treating pain comprising paracetamol and buspirone | |
| BRPI0717919A2 (en) | "PROPHYLATIC OR THERAPEUTIC AGENT FOR ALOPECY" | |
| CN101379054A (en) | Piperidine derivatives as CXCR3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131120 Termination date: 20190427 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |